Aadi Bioscience, Inc. Common Stock

Aadi Bioscience, Inc. Common Stock

AADI Stock Report Card

$

VolatilityTechnicalsProfitPerformanceEarnings

D

Performance

Score: 10/100

F

AADI returned -59.10% in the last 12 months. Based on the other stocks in it's sector with an average return of -31.76%, it's performance is below average giving it a grade of 10 of 100.

Technicals

Score: 14/100

F

AADI receieves a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

Earnings

Score: 30/100

D

AADI has missed earnings 4 times in the last 20 quarters.

Profit

Score: 15/100

F

Out of the last 13 quarters, AADI has had 2 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

Score: 42/100

C

AADI has had a lower than average amount of volatility over the last 12 months giving it a grade of 41 of 100.

Aadi Bioscience, Inc. Common Stock Summary

Nasdaq / AADI
Healthcare
Biotechnology
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
pluto logo
Los Angeles, CA